will compound pharmacies stop making semaglutide will - Is compoundedsemaglutideFDA-approved State-licensed pharmacies must stop making most compounded semaglutide Will Compound Pharmacies Stop Making Semaglutide? The FDA's Policy Shift Explained

Is compounded tirzepatide going away The landscape of semaglutide availability has shifted significantly in recent months, leaving many patients and healthcare providers wondering: will compound pharmacies stop making semaglutide? The answer is largely yes, with notable distinctions for different types of compounding facilities and specific timelines. This change stems directly from the U.S. Food and Drug Administration's (FDA) recent decision to declare the national shortage of semaglutide injection products officially over佛历2568年5月14日—Forsemaglutide, smallpharmacieshad tostop productionby April 22, while large compounders have until May 22. The move has left many US ....

For a period, compounding pharmacies played a crucial role in bridging the gap created by the shortages of FDA-approved semaglutide formulations, such as Ozempic® and Wegovy®.Compounders sue FDA again over declaring end ... During this time, many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 medications. Authorized by the FDA to source active ingredients and produce these medications, these pharmacies helped ensure access for patients seeking treatment for type 2 diabetes and chronic weight management.佛历2568年5月27日—With both companies' GLP-1 drugs no longer in shortage,compounding pharmaciesand other companies would no longer be able to sellcompounded... However, with the removal of semaglutide from the drug shortage list, the regulatory environment for compounded versions has changed佛历2568年3月18日—As things currently stand,compounding pharmaciesand outsourcing facilitieswillnot be able to preparesemaglutidecopies again, said Scott ....

The FDA's clarification of policies for compounders marks a significant turning point. As of February 2025, semaglutide was removed from the list, triggering new directives for compounding pharmacies. These directives generally state that compounding pharmacies must stop making and selling semaglutide injections when FDA-approved versions are once again readily available.FDA stops sale of copycat versions of Ozempic and Wegovy

The specific timelines for this transition vary depending on the type of compounding facility:

* 503A Compounding Pharmacies: These are typically smaller, state-licensed pharmacies. For semaglutide, these pharmacies had to stop production by April 22, 2025. This means they can no longer regularly manufacture compounded semaglutide佛历2568年4月29日—503A compounding pharmacies may continue to compoundsemaglutide injection productsuntil April 22, 2025. ... semaglutide injection products will ....

* 503B Outsourcing Facilities: These are larger facilities that handle compounding for wholesale distribution.佛历2568年2月28日—The FDA's recent decision to removesemaglutidefrom the drug shortage list marks a significant shift forcompounding pharmacies. The FDA will allow nationally licensed outsourcing facilities to continue to produce semaglutide until May 22, 2025What to know about the compounded semaglutide ban. Therefore, large compounders will still have only until May 22 to comply and stop producing their versions of semaglutide.

This move has raised concerns about the affordability and accessibility of weight loss medications, as compounded semaglutide often presented a more cost-effective option for some individualsCompanies find ways around end of GLP-1 shortage. The FDA's increased scrutiny and subsequent restrictions on selling compounded products are aimed at ensuring product quality and patient safety, prioritizing the use of FDA-approved drugs when they are available.佛历2568年5月21日—The grace period for manufacturers tostopproducing andselling compoundedtirzepatide ended in March, and Thursday is the final cutoff date ...

Despite these changes, some entities are exploring ways to continue offering compounded semaglutide. For instance, online telehealth platforms like Hims & Hers have indicated they may continue offering compounded semaglutide to eligible patients, navigating the new regulationsHims & Hers warns it may stop selling compounded weight .... The specifics of how these platforms will operate under the new guidelines are still evolving.

It is important for patients to understand that compounded semaglutide is not FDA-approved. While compounded GLP-1s were instrumental during shortages, the regulatory shift reflects the FDA's intention to steer patients towards FDA-approved semaglutide injection products now that supply issues have been resolved佛历2568年2月24日—On Friday, the Food and Drug Administration said that it had removed the drug from its shortage list and gave compounders 60-90 days tostop.... The availability of compounded tirzepatide also faces similar restrictions as it too was removed from the shortage list.

In summary, while compounding pharmacies were essential in providing access to semaglutide during a period of shortages, the FDA's recent policy changes mean that the production and distribution of compounded semaglutide are being phased out. Patients seeking semaglutide for diabetes or weight management should consult their healthcare providers to discuss FDA-approved treatment options and understand the current availability of medicationsThe Semaglutide Shortage Is Ending - Sesame. The era of widespread compounding pharmacies regularly making semaglutide injections is coming to an end, as the market returns to a more stable supply of approved alternatives佛历2568年11月18日—The FDA declared thesemaglutideshortage over. Because of this,compounded semaglutideis only available in certain situations..